Hyperfine, Inc. Class A (HYPR)

Over the past six months, Hyperfine's stock price has experienced significant movement, showing a 69.47% increase as of April 9, 2025. The stock declined by 4.55% after the Q3 2025 earnings announcement, where Hyperfine reported a net loss of $0.14 per share and revenue of $3.4 million. Despite this, the company achieved sequential revenue growth of 27% and a record gross margin of 53.8%. In October 2025, Hyperfine announced and priced a $17.5 million public offering and provided optimistic Q4 guidance, expecting revenue between $5 million and $6 million.

Hyperfine, Inc. expects "some summer seasonality impact" on its revenue, particularly due to an increased mix of international revenue, suggesting that demand for its products and services may fluctuate with seasonal patterns.

Hyperfine, Inc. (NASDAQ: HYPR) is a health technology company focused on revolutionizing medical imaging through its portable magnetic resonance imaging (MRI) system. The company operates within the Healthcare sector, specifically in the Medical Devices industry, and is also categorized under Health Technology and Biotechnology. Hyperfine's core business involves the production, supply, service, and commercialization of MRI products, including the Swoop® Portable MR Imaging System, which utilizes an ultra-low-field magnet and advanced artificial intelligence (AI) to produce diagnostic images at the patient's bedside. The company also offers support and technical assistance services, as well as the Hyperfine Image Viewer, a cloud picture archiving and communication system. Hyperfine's business model includes the sale of its proprietary hardware and recurring revenue from software and services, such as its Optive AI™ software.

Hyperfine, Inc. serves a broad international market, reaching customers in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand through direct sales and distributors. The company is actively expanding its global presence, with plans for further international growth and potential regulatory approval in India in the second half of 2025.

Hyperfine has focused on innovation and market expansion, contributing to its brand reputation. The company received FDA clearance for its ninth-generation AI-powered software and its next-generation Optive AI™ software. Hyperfine has also expanded its global market reach through new distribution partnerships, exiting 2024 with 13 partners. The company has actively participated in leading conferences and was awarded a $3.7 million grant to advance global brain health. Key executive appointments in June 2025 also aimed to strengthen its leadership in AI-powered portable MRI.

Hyperfine, Inc. (HYPR) ownership is distributed among institutional shareholders, company insiders, and retail investors. Institutional shareholders hold 11.25% of the company, insiders own 27.75%, and retail investors account for 61.01%. Jonathan M. Rothberg is the largest individual shareholder, holding 17.56% of the company's shares. Major institutional owners include Vanguard Group Inc., Fosun International Ltd, Northern Trust Corp, Alphabet Inc., Catalio Capital Management LP, Geode Capital Management LLC, and Blackrock Inc.